Tumor News and Research

RSS

Immune-suppressing protein may predict how patients respond to treatment

The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found.

27 Nov 2014

TET1 enzyme may be important target for cancer diagnostics, treatment

Mutations in the KRAS gene have long been known to cause cancer, and about one third of solid tumors have KRAS mutations or mutations in the KRAS pathway. KRAS promotes cancer formation not only by driving cell growth and division, but also by turning off protective tumor suppressor genes, which normally limit uncontrolled cell growth and cause damaged cells to self-destruct.

27 Nov 2014

Pathology specialist publishes invited commentary on breast cancer gene screening

There has been much recent debate on the benefits and risks of screening for breast cancer using BRCA1 and BRCA2 mutations in the general adult population.

27 Nov 2014

Researchers find unusual role of lactate in metabolism of alveolar soft part sarcoma

Researchers from Huntsman Cancer Institute at the University of Utah discovered the unusual role of lactate in the metabolism of alveolar soft part sarcoma (ASPS), a rare, aggressive cancer that primarily affects adolescents and young adults. The study also confirmed that a fusion gene is the cancer-causing agent in this disease.

27 Nov 2014

Researchers discover why advanced melanoma patients respond to pembrolizumab drug

Work supported by the Stand Up To Cance - Cancer Research Institute - Immunology Translational Research Dream Team, launched in 2012 to focus on how the patient's own immune system can be harnessed to treat some cancers have pioneered an approach to predict why advanced melanoma patients respond to a new life-saving melanoma drug.

27 Nov 2014

New research brings personalized cancer vaccine approach one step closer to reality

In the near future, physicians may treat some cancer patients with personalized vaccines that spur their immune systems to attack malignant tumors. New research led by scientists at Washington University School of Medicine in St. Louis has brought the approach one step closer to reality.

27 Nov 2014

Interventional X-ray guidance device may reduce radiation exposure of liver cancer patients

Johns Hopkins researchers report that their test of an interventional X-ray guidance device approved by the U.S. Food and Drug Administration in 2013 has the potential to reduce the radiation exposure of patients undergoing intra-arterial therapy (IAT) for liver cancer.

27 Nov 2014

Researchers uncover easily detectable, 'pre-malignant' state in the blood

Researchers from the Broad Institute of MIT and Harvard, Harvard Medical School, and Harvard-affiliated hospitals have uncovered an easily detectable, "pre-malignant" state in the blood that significantly increases the likelihood that an individual will go on to develop blood cancers such as leukemia, lymphoma, or myelodysplastic syndrome.

27 Nov 2014

BWH researchers identify two-faced role of TIM-3 protein

A Brigham and Women's Hospital-led team has identified a long sought-after partner for a key immune protein, called TIM-3, that helps explain its two-faced role in the immune system -- sometimes dampening it, other times stimulating it. This newly identified partner not only sheds light on the inner workings of the immune system in diseases such as HIV, autoimmunity, and cancer, but also provides a critical path toward the development of novel treatments that target TIM-3.

26 Nov 2014

CARsgen announces completion of series A financing

CARsgen, a leader in the development of Chimeric Antigen Receptors T (CAR-T) cell immunotherapy to treat a variety of cancers, today announced the completion of a series A financing led by BVCF, a China-based healthcare private equity fund.

26 Nov 2014

Eminent molecular cell biologist awarded GRC fellowship

The Gutenberg Research College of Johannes Gutenberg University Mainz has awarded the coveted GRC fellowship to Professor Krishnaraj Rajalingam. In the upcoming years, he will lead a research team at the Research Center for Immunotherapy at Mainz University.

26 Nov 2014

Research findings could lead to better tests for predicting breast cancer spread

A study combining tumor cells from patients with breast cancer with a laboratory model of blood vessel lining provides the most compelling evidence so far that a specific trio of cells is required for the spread of breast cancer. The findings could lead to better tests for predicting whether a woman's breast cancer will spread and to new anti-cancer therapies.

26 Nov 2014

Janssen submits YONDELIS NDA for treatment of advanced soft tissue sarcoma

PharmaMar announces that Janssen Research & Development, LLC has submitted a New Drug Application (NDA) for YONDELIS (trabectedin) to the U.S. Food and Drug Administration for the treatment of patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy including an anthracycline.

26 Nov 2014

MACROD2 gene may explain why some breast cancers are resistant to tamoxifen

After mining the genetic records of thousands of breast cancer patients, researchers from the Johns Hopkins Kimmel Cancer Center have identified a gene whose presence may explain why some breast cancers are resistant to tamoxifen, a widely used hormone treatment generally used after surgery, radiation and other chemotherapy.

25 Nov 2014

Adults diagnosed with retinoblastoma as infants perform better on tasks, study finds

Most long-term survivors of retinoblastoma, particularly those who had been diagnosed with tumors by their first birthdays, have normal cognitive function as adults, according to a St. Jude Children's Research Hospital study. The research, which appears in the current issue of the journal Cancer, found that the vast majority of survivors work full time, live independently and fulfill other milestones of adult life.

25 Nov 2014

Study identifies H3.3 protein as key regulator in cellular senescence

Changes to the structure of the protein histone H3.3 may play a key role in silencing genes that regulate cancer cell growth, according to a study led by researchers from the Icahn School of Medicine at Mount Sinai and published online this month in the journal Nature Communications.

23 Nov 2014

Researchers discover why only some patients respond to ipilimumab drug

A collaborative team of leaders in the field of cancer immunology from Memorial Sloan Kettering Cancer Center has made a key discovery that advances the understanding of why some patients respond to ipilimumab, an immunotherapy drug, while others do not. MSK was at the forefront of the clinical research that brought this CTLA-4 blocking antibody to melanoma patients.

23 Nov 2014

EDDA Technology to introduce IQQA-BodyImaging, cloud-based OnDemand service at RSNA 2014

EDDA Technology, a global leading provider in advanced real-time interactive quantitative imaging solutions, announced today that the company has received FDA clearance on IQQA-BodyImaging.

21 Nov 2014

MD Anderson study sheds light on little-known protein complex

A study at The University of Texas MD Anderson Cancer Center led by Mong-Hong Lee, Ph.D., a professor of molecular and cellular oncology, has demonstrated the significance of CSN6 in regulating Myc which may very well open up a new pathway for treating and killing tumors.

21 Nov 2014

New course underlines the importance of early detection of lung cancer

In Japan, 40 percent of lung cancer cases are detected on early stages and treated with a high probability of remission; in the US 20 percent of cases have that possibility, while in Mexico, in the National Cancer Institute (INCan), only 1.2 percent of patients are diagnosed at an early stage.

21 Nov 2014

Tumor News and Research

Immune-suppressing protein may predict how patients respond to treatment

TET1 enzyme may be important target for cancer diagnostics, treatment

Pathology specialist publishes invited commentary on breast cancer gene screening

Researchers find unusual role of lactate in metabolism of alveolar soft part sarcoma

Researchers discover why advanced melanoma patients respond to pembrolizumab drug

New research brings personalized cancer vaccine approach one step closer to reality

Interventional X-ray guidance device may reduce radiation exposure of liver cancer patients

Researchers uncover easily detectable, 'pre-malignant' state in the blood

BWH researchers identify two-faced role of TIM-3 protein

CARsgen announces completion of series A financing

Eminent molecular cell biologist awarded GRC fellowship

Research findings could lead to better tests for predicting breast cancer spread

Janssen submits YONDELIS NDA for treatment of advanced soft tissue sarcoma

MACROD2 gene may explain why some breast cancers are resistant to tamoxifen

Adults diagnosed with retinoblastoma as infants perform better on tasks, study finds

Study identifies H3.3 protein as key regulator in cellular senescence

Researchers discover why only some patients respond to ipilimumab drug

EDDA Technology to introduce IQQA-BodyImaging, cloud-based OnDemand service at RSNA 2014

MD Anderson study sheds light on little-known protein complex

New course underlines the importance of early detection of lung cancer

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News